TAKEDA PHARMACEUTICAL COMPANY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,089 JPY | -0.02% |
|
+0.49% | +0.86% |
| Apr. 26 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
| Apr. 26 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 7,029,161 | 5,153,364 | 6,229,971 | 5,423,454 | 6,762,204 | 6,415,371 | - | - |
| Enterprise Value (EV) 1 | 12,054,743 | 9,609,054 | 9,862,522 | 8,919,170 | 10,611,015 | 10,186,084 | 9,853,178 | 9,541,050 |
| P/E ratio | 40 x | 118 x | 16.6 x | 23.8 x | 21.3 x | 46.4 x | 27.6 x | 22.5 x |
| Yield | 3.98% | 5.44% | 4.52% | 5.15% | 4.14% | 4.6% | 4.64% | 4.72% |
| Capitalization / Revenue | 3.35 x | 1.57 x | 1.95 x | 1.52 x | 1.68 x | 1.56 x | 1.59 x | 1.56 x |
| EV / Revenue | 5.75 x | 2.92 x | 3.08 x | 2.5 x | 2.63 x | 2.48 x | 2.45 x | 2.32 x |
| EV / EBITDA | 25.3 x | 14 x | 9.23 x | 8.54 x | 9.19 x | 9.74 x | 8.98 x | 8.27 x |
| EV / FCF | -4.81 x | 9.99 x | 16 x | 8.92 x | 28.7 x | 29.5 x | 14.6 x | 14.4 x |
| FCF Yield | -20.8% | 10% | 6.26% | 11.2% | 3.49% | 3.39% | 6.86% | 6.97% |
| Price to Book | 1.36 x | 1.09 x | 1.2 x | 0.95 x | 1.06 x | 1.01 x | 1.02 x | 1.01 x |
| Nbr of stocks (in thousands) | 1,554,780 | 1,557,849 | 1,563,355 | 1,550,444 | 1,554,530 | 1,568,934 | - | - |
| Reference price 2 | 4,521 | 3,308 | 3,985 | 3,498 | 4,350 | 4,089 | 4,089 | 4,089 |
| Announcement Date | 5/14/19 | 5/13/20 | 5/11/21 | 5/11/22 | 5/11/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,097,200 | 3,291,200 | 3,197,812 | 3,569,006 | 4,027,478 | 4,099,317 | 4,028,429 | 4,107,599 |
| EBITDA 1 | 477,415 | 684,057 | 1,068,940 | 1,043,995 | 1,154,905 | 1,046,202 | 1,097,806 | 1,153,436 |
| EBIT 1 | 205,000 | 100,400 | 509,269 | 460,844 | 490,505 | 267,999 | 429,150 | 489,383 |
| Operating Margin | 9.77% | 3.05% | 15.93% | 12.91% | 12.18% | 6.54% | 10.65% | 11.91% |
| Earnings before Tax (EBT) 1 | 94,896 | -60,754 | 366,235 | 302,571 | 375,090 | 132,641 | 314,185 | 387,676 |
| Net income 1 | 109,100 | 44,200 | 376,005 | 230,059 | 317,017 | 134,022 | 233,930 | 291,583 |
| Net margin | 5.2% | 1.34% | 11.76% | 6.45% | 7.87% | 3.27% | 5.81% | 7.1% |
| EPS 2 | 113.0 | 28.00 | 240.7 | 147.1 | 204.3 | 88.13 | 148.1 | 182.1 |
| Free Cash Flow 1 | -2,507,219 | 961,871 | 617,401 | 999,853 | 370,054 | 344,948 | 675,738 | 664,805 |
| FCF margin | -119.55% | 29.23% | 19.31% | 28.01% | 9.19% | 8.41% | 16.77% | 16.18% |
| FCF Conversion (EBITDA) | - | 140.61% | 57.76% | 95.77% | 32.04% | 32.97% | 61.55% | 57.64% |
| FCF Conversion (Net income) | - | 2,176.18% | 164.2% | 434.61% | 116.73% | 257.38% | 288.86% | 228% |
| Dividend per Share 2 | 180.0 | 180.0 | 180.0 | 180.0 | 180.0 | 188.0 | 189.9 | 192.9 |
| Announcement Date | 5/14/19 | 5/13/20 | 5/11/21 | 5/11/22 | 5/11/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2020 S1 | 2020 S2 | 2021 S1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 S1 | 2025 Q3 | 2025 Q4 | 2026 S1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,660,200 | 1,631,000 | 1,590,785 | 844,797 | 1,794,400 | 901,294 | 873,289 | 972,465 | 1,002,340 | 1,974,800 | 1,096,551 | 956,200 | 1,058,618 | 1,043,089 | 2,101,707 | 1,111,200 | 899,902 | 1,038,000 | 1,044,000 | 2,034,000 | 1,106,000 | 959,000 | 2,060,000 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | - | - | 249,972 | 340,072 | 133,355 | - | 291,975 | 207,900 | - | - | - | - | - | - |
| EBIT 1 | 50,300 | 50,100 | 215,588 | 97,448 | 346,000 | 116,484 | -1,619 | 150,515 | 104,485 | 255,000 | 146,990 | 88,600 | 168,571 | -49,341 | 119,230 | 104,900 | 50,750 | 94,000 | - | 185,500 | - | - | 210,500 |
| Operating Margin | 3.03% | 3.07% | 13.55% | 11.54% | 19.28% | 12.92% | -0.19% | 15.48% | 10.42% | 12.91% | 13.4% | 9.27% | 15.92% | -4.73% | 5.67% | 9.44% | 5.64% | 9.06% | - | 9.12% | - | - | 10.22% |
| Earnings before Tax (EBT) 1 | -27,557 | -33,197 | 125,561 | 61,447 | 284,425 | 72,193 | -54,047 | 155,473 | 64,549 | 220,022 | 107,153 | 47,900 | 135,033 | -95,980 | 39,053 | 61,300 | 18,376 | 42,500 | - | 92,500 | - | - | 127,500 |
| Net income 1 | 33,200 | 11,000 | 86,548 | -16,778 | 183,600 | 57,769 | -11,358 | 105,014 | 61,786 | 166,800 | 119,127 | 31,100 | 89,395 | -48,030 | 41,365 | 105,700 | -18,644 | 32,500 | - | 70,500 | - | - | 97,500 |
| Net margin | 2% | 0.67% | 5.44% | -1.99% | 10.23% | 6.41% | -1.3% | 10.8% | 6.16% | 8.45% | 10.86% | 3.25% | 8.44% | -4.6% | 1.97% | 9.51% | -2.07% | 3.13% | - | 3.47% | - | - | 4.73% |
| EPS 2 | 21.00 | - | 55.45 | -10.27 | 117.0 | 37.01 | -6.950 | 67.94 | 40.06 | 108.0 | 76.70 | 20.03 | 57.51 | -31.00 | 26.51 | 67.38 | 0.7722 | 20.70 | - | 44.90 | - | - | 62.10 |
| Dividend per Share 2 | 90.00 | - | 90.00 | - | 90.00 | - | - | - | - | - | - | - | - | 94.00 | 94.00 | - | 94.00 | - | 94.00 | - | - | 94.00 | - |
| Announcement Date | 10/31/19 | 5/13/20 | 10/29/20 | 10/28/21 | 10/28/21 | 2/3/22 | 5/11/22 | 7/28/22 | 10/27/22 | 10/27/22 | 2/2/23 | 5/11/23 | 7/27/23 | 10/26/23 | 10/26/23 | 2/1/24 | - | - | - | - | - | - | - |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 5,025,582 | 4,455,690 | 3,632,551 | 3,495,716 | 3,848,811 | 3,770,713 | 3,437,808 | 3,125,679 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 10.53 x | 6.514 x | 3.398 x | 3.348 x | 3.333 x | 3.604 x | 3.132 x | 2.71 x |
| Free Cash Flow 1 | -2,507,219 | 961,871 | 617,401 | 999,853 | 370,054 | 344,948 | 675,738 | 664,805 |
| ROE (net income / shareholders' equity) | 3% | 0.9% | 7.6% | 4.2% | 5.3% | 2.13% | 3.88% | 4.76% |
| ROA (Net income/ Total Assets) | 1.06% | -0.46% | 2.85% | 2.32% | 2.76% | 1.03% | 1.94% | 2.52% |
| Assets 1 | 10,334,963 | -9,710,018 | 13,209,937 | 9,918,859 | 11,467,260 | 12,997,037 | 12,085,642 | 11,583,413 |
| Book Value Per Share 2 | 3,319 | 3,032 | 3,309 | 3,666 | 4,087 | 4,052 | 4,003 | 4,067 |
| Cash Flow per Share 2 | 397.0 | 403.0 | 599.0 | 520.0 | 632.0 | 704.0 | 660.0 | 676.0 |
| Capex 1 | 134,114 | 217,710 | 236,468 | 186,037 | 633,689 | 516,170 | 366,694 | 371,598 |
| Capex / Sales | 6.39% | 6.61% | 7.39% | 5.21% | 15.73% | 12.59% | 9.1% | 9.05% |
| Announcement Date | 5/14/19 | 5/13/20 | 5/11/21 | 5/11/22 | 5/11/23 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,089
JPY
Average target price
4,779
JPY
Spread / Average Target
+16.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.86% | 40.76B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 4502 Stock
- Financials Takeda Pharmaceutical Company Limited
